PPDPF alleviates hepatic steatosis through inhibition of mTOR signaling

Non-alcoholic fatty liver disease (NAFLD) has become the most prevalent chronic liver disease in the world, however, no drug treatment has been approved for this disease. Thus, it is urgent to find effective therapeutic targets for clinical intervention. In this study, we find that liver-specific kn...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Ning, Wang, Yi-Kang, Xu, Sheng, Ni, Qian-Zhi, Zheng, Qian-Wen, Zhu, Bing, Cao, Hui-Jun, Jiang, Hao, Zhang, Feng-Kun, Yuan, Yan-Mei, Zhang, Er-Bin, Chen, Tian-Wei, Xia, Ji, Ding, Xu-Fen, Chen, Zhen-Hua, Zhang, Xiu-Ping, Wang, Kang, Cheng, Shu-Qun, Qiu, Lin, Li, Zhi-Gang, Yu, Yong-Chun, Wang, Xiao-Fan, Zhou, Bin, Li, Jing-Jing, Xie, Dong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8144412/
https://www.ncbi.nlm.nih.gov/pubmed/34031390
http://dx.doi.org/10.1038/s41467-021-23285-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8144412/
https://www.ncbi.nlm.nih.gov/pubmed/34031390
http://dx.doi.org/10.1038/s41467-021-23285-8

Ejemplares similares